TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Left ventricular end-systolic volume (LVESV) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Day 3 Embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Day 5 Embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Presence of Biomarker(s) Predictive of Anti-epileptic Drug Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants scheduling appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stress test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life due to urinary symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of patients with Prostate Artery Embolization that did not have prostate operation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptom severity score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postprandial glycaemia following breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial insulinaemia following breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial glycaemia following ad libitum lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial insulinaemia following ad libitum lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of Inflammatory Lesions of Rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of Erythema and Telangiectasia of Rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite Peripartum Infection or Death
Endpoint domain: Mortality/survival
Primary endpoint: Durations of cortical silent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of motor evoked potential amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical Inhibitory Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TB incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Expression of peripheral T lymphocytes subset cluster of differentiation3 percentage (CD3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of peripheral T lymphocytes subset cluster of differentiation 4 percentage (CD4+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of peripheral T lymphocytes subset cluster of differentiation 8 percentage (CD8+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pattern of Change in Severity of Chief Complaint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS Quality of Life Scales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-reported Assessment of Change in Overall Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of XL647
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of XL647
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ESSDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of concentration of IL-6 in venous blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of people with low cardiac output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of people with postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Severe Oral Mucositis (CTCAE Grade 3-5)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe Oral Mucositis (WHO Grade 3-4)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of acute hematologic toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Allele frequency of genetic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum M protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GERD control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Visual Analogue Scale 7 (VAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SCATIII Symptom Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of chloroprocaine 1% for sensory anesthesia block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative respiratory complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abnormal Plantar Pressure Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of individuals receiving a standardized program of pretest education who then proceed to genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportions of individuals who choose to receive the results through their primary care providers or through the study-provided expert staff
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Psychosocial impact of genetic population screening utilizing a digital health solution
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of failure of conservative resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Optimal maneuvers in corneal transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative Percentage of Participants by Heavy Drinking Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection rate of dysplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Healing of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Facial Investigator's Global Assessment (IGA) score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of identifying PVC or VT origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Anxiety Depression Scale-Total (HADS-Total)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gene expression levels of SNCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression levels of LRRK2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression levels of Parkin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression levels of alpha-synuclein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression levels of LRRK2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression levels of Parkin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum metabolic cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cerebral T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Area Under the Curve (AUC) of Total Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of dynamic CTP and CT-FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of device and procedure related complications
Endpoint domain: Adverse events/effects
Primary endpoint: NIH-CPSI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of errors committed during a walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle injury scoring scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Performance and Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Eczema Area Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Child-Pugh score post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOFA score post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ASIA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liver elasticity measured by ARFI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of grade 2-4 acute graft-versus-host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Secondary caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maxillofacial fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Major Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Symptomatic Atrial Fibrillation, Atrial Flutter, and Atrial Tachycardia Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 3-5 Gastrointestinal Perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With MDI Misuse
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial C-peptide response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in HPV16/18 Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Impact on primary care physician behavior towards global cardiovascular risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feeling of Satisfaction with Inhaler
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline generalized anxiety disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain severity and pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline irritable bowels syndrome severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall mortality until discharge or 60 days after admission
Endpoint domain: Mortality/survival
Primary endpoint: one-point increase in the quality score of OARSI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: joint space reduction greater than the smallest reliable detectable difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in joint space of 0.5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in false alarms
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and grade of pocket hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inter-sample variability of sputum concentration (% solids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Sinus Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of AZD4831 excreted (CumAe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative amount of AZD4831 excreted as a percentage of the administered dose (CumFe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage change in bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Technical skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Objective Sleep Quality at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Subjective Sleep Quality at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline Cognitive Functioning at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in NK cells, T reg and Th17 cells frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in secretion levels of cytokines related to Treg and Th17 cells (IL-17, IL-21)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in expression of cytokines gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of Differences Between Noninvasive and Laboratory Hemoglobin Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation with soft tissue response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain at injection site: grade
Endpoint domain: Adverse events/effects
Primary endpoint: Infection at injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding at injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness on OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Lactating Women With Serum IgG Antibodies to Laronidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of IgG Antibody Titers to Laronidase in Lactating Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Women Who Breastfed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activity-specific Balance Confidence Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 3D Motion Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay before full refunctionalization of the small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biochemically verified alcohol and/or drug abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Primary endpoint: Memory Recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of subjects with RM3log after imatinib discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of sensory nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC48-72 hrs of Diclofenac gel in tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Diclofenac gel in tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC48-72 hrs of Diclofenac gel in roll-on device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Diclofenac gel in roll-on device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Residual Disease Negative Complete Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained Reduction in Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Atrial Fibrillation (AF) 6 questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Goal Attainment Scaling (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Euro-Qol: EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma HIV-1 RNA < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical Flicker Fusion (CFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate and Delayed Recall of Supraspan Word Lists (WRI and WRD)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Compensatory Tracking Task (CTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Symbol Substitution Test (DSST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of Sentinel Adverse Respiratory Events (AREs)
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary drug screen results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Epi-LASIK
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Epi-LASIK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTproCNP level in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of lymph node dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Patients Free of Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Numeric Rating Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamstrings length/popliteal angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Primary neurologic outcome measured by the Glasgow Outcome Score - Extended
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline In Serum Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Of Adverse Events Of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of Ki67-positive Cells Before and After Palifermin Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local and Systemic Reactions After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Virus-Confirmed Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects completing 4 doses of Avelumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 2-h pp glycaemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-h pp glycaemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID) Over 8 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose of intratumoral urelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Log Transformed sAUC0-t Standardized to One Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time return to home activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PDA re-opening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final cure at six month follow up
Endpoint domain: Mortality/survival
Primary endpoint: Psychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coronary artery lumen expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of the Intervention (time)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to complete 10 trays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic disease evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes